Liquidia’s $380.7 million settlement redraws Yutrepia’s patent boundary

The story

Liquidia and United Therapeutics have agreed to end six intertwined lawsuits while preserving a narrower commercial path for Yutrepia, Liquidia’s inhaled treprostinil powder. Under the global settlement announced late October 13, Yutrepia can remain available for pulmonary arterial hypertension, or PAH. Liquidia, however, will remove pulmonary hypertension associated with interstitial lung disease, or PH-ILD, from the product’s label, stop promoting that use and pay a net $380.7 million across several transactions through April 2027.

The deal follows a consequential September 30 ruling in Delaware. The court found that Yutrepia infringed claims 1 and 14 of United Therapeutics’ U.S. Patent No. 11,826,327 and that Liquidia had not proved those claims invalid. The claims cover specified treatment of PH-ILD with inhaled treprostinil. Liquidia agreed not to appeal. The settlement does not constitute an admission of liability on the remaining claims, and the covered actions are to be dismissed with prejudice after the initial payment conditions are met.

The money is split among several obligations. United Therapeutics’ SEC filing says Liquidia will pay it $330.4 million: $185 million for past PH-ILD sales within 30 business days, followed by two installments of $72.7 million for estimated continuing PH-ILD sales, due by January 31 and April 30, 2027. United will pay Liquidia $10 million to resolve separate antitrust litigation involving generic Treprostinil Injection. Liquidia will also pay an aggregate $60.3 million to Sandoz, Henderson SPV and PBM RG Holdings for their interests in that antitrust case. The resulting net outflow is $380.7 million.

The operational restrictions are as important as the cash. Liquidia said it has submitted a supplement asking the Food and Drug Administration to remove PH-ILD from Yutrepia’s label. Until the FDA acts, the company may continue selling existing product under the settlement, but it must immediately stop advertising, detailing and proactively educating clinicians about PH-ILD. Once the label change is approved, it must stop selling product bearing that indication. PAH sales may continue without interruption.

The agreement also narrows how the medicine reaches the market. Future promotion is limited to healthcare providers known to treat Group 1 PAH. Liquidia must send transition communications to clinicians and payers, and its referral process must require confirmation of a PAH diagnosis. These controls are unusual in their specificity, translating a patent judgment into prescriber targeting, payer communication and patient-enrollment rules rather than imposing a blanket product withdrawal.

Research activity is affected too. United’s filing says Liquidia must terminate the PH-ILD cohorts in its ASCENT study and stop publishing or disseminating data from those cohorts until the ’327 patent expires in February 2042. That is a contractual settlement term, not an FDA safety finding. Liquidia said it will continue other Yutrepia studies and development of L606, a twice-daily extended-release treprostinil formulation, but the agreement does not protect indications other than PAH or new treprostinil-containing products from future patent assertions.

The litigation being closed is broader than the Delaware case. It includes a United suit over U.S. Patent No. 11,357,782, Liquidia’s countervailing suit over U.S. Patent No. 10,898,494, two North Carolina matters alleging trade-secret misappropriation and contract breach, and the Sandoz-RareGen antitrust case. United may continue claims against former Liquidia executive Robert Roscigno. The companies also exchanged covenants not to sue and not to challenge specified patents and related applications within the settlement’s defined scope.

For Liquidia, the bargain preserves the product’s core PAH franchise after a damaging patent ruling. The company reported preliminary, unaudited third-quarter Yutrepia sales of $222.7 million and $396.1 million in cash and equivalents at September 30. Those figures provide context for its claim that the payments can be funded from cash and product sales, but they are not a guarantee: the company still faces a large near-term outflow and a smaller addressable label than it had before the settlement.

INNOVOX analysis: this is not simply a damages check exchanged for peace. The parties have used intellectual-property rights to draw a line through one molecule, one delivery format and two disease indications. Liquidia retains a commercialization channel in PAH; United protects the PH-ILD segment covered by the ’327 patent; and the settlement reaches into promotion, prescribing workflows and clinical evidence. That structure shows why pharmaceutical patent disputes can reshape competition long before a product is removed from shelves.

What to watch next is execution. The FDA must review the label supplement, the first net payment must clear, dismissal papers must be filed and third-party approvals—including Sandoz consent—must be obtained where required. Investors and patients will then see whether PAH-only demand sustains Yutrepia’s momentum. Longer term, the most important boundary is outside this agreement: United explicitly retains the ability to assert patents against other Liquidia development programs and future treprostinil products.

INNOVOX analysis

The agreement does more than price past infringement. It turns a patent boundary into a commercial operating plan: one indication remains open, another is removed from the label, marketing channels narrow and a research program is curtailed. That makes the settlement a revealing example of how life-sciences intellectual property can divide markets at the level of indication and evidence generation rather than simply remove a product from sale.

What to watch

Watch for FDA action on Liquidia’s label supplement, completion of the initial payments and case dismissals, required Sandoz consent, Yutrepia’s PAH-only sales trajectory and any future patent disputes over Liquidia’s L606 program or new treprostinil products.